GenMark Diagnostics (GNMK) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
GenMark Diagnostics Reports Q2 Financial Results
July 28, 2016 4:09 PM EDT
Second Quarter Revenue Increased 64% Versus Prior Year to $12.5
million
ePlex® Systems Installed at
Twelve European Customers
ePlex FDA Submission Expected in
Fourth Quarter
CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the second quarter ended June 30, 2016.
Revenue for the second quarter of 2016 was $12.5 million, an increase of 64% over the prior year period.
Gross profit for the second quarter of 2016 was $7.8 million, or 62% of revenue, compared with $4.4... More
